Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialEurope PMCOpen access

Safety and Efficacy of Micronized Acellular Dermal Matrix Injection for Correction of Moderate to Severe Nasolabial Folds: A Double-Blind, Multicenter, Randomized Controlled, Non-inferior Clinical Trial

Zhang C., Chang X., Chen L., Wang H., Feng G., Zheng W.

Randomized Controlled Trial with a reported sample of 86 on Skin Aging, Facial Rejuvenation, published in Aesthetic Plast Surg (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Aesthetic Plast Surg (2026)
Reported sample size
86
Source database
Europe PMC
PMID
41381953
PMCID
PMC13219193
DOI
10.1007/s00266-025-05494-4

Abstract (original English)

Background Nasolabial folds (NLFs) are prominent facial lines that deepen with age and may adversely affect facial aesthetics and psychosocial confidence. Injectable fillers, including micronized acellular dermal matrix (mADM), offer minimally invasive correction; however, clinical evidence for mADM's safety and efficacy remains limited. We conducted a double-blind, multicenter, randomized controlled trial to compare an mADM filler (Regenfil) with a regulatory agency-approved cross-linked collagen filler (Sunmax Collagen Implant I-Plus). Methods Adults aged ≥18 years with Wrinkle Severity Rating Scale (WSRS) grade 3 or 4 NLFs were randomized to receive mADM or collagen. Six weeks after the initial treatment, a protocol-defined supplemental injection was permitted if additional correction was needed. Outcomes were assessed 6 weeks, 3 months, and 6 months after the last treatment. Efficacy endpoints included blinded-evaluator WSRS, Global Aesthetic Improvement Scale (GAIS) rated by injectors and participants, and participant satisfaction. The prespecified primary endpoint was the percentage of participants achieving a >1-grade WSRS improvement simultaneously on both left and right NLFs. Safety was evaluated by monitoring device-related adverse events and local injection-site reactions. Results Of 202 randomized participants, 175 completed all required follow-ups for safety and ef

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansCollagenTreatment OutcomeCosmetic TechniquesDouble-Blind MethodEstheticsSkin AgingAdultAgedMiddle Aged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research